20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
2024 Planning for Prevention of Parkinson’s Conference
The 2024 Planning for Prevention of Parkinson’s: A Trial Design Forum conference will be held from May 5-7 in Boston, Massachusetts, US, this conference is intended to bring together Parkinson’s research stakeholders, academics, and patient advocates to share information on and inform future Parkinson’s prevention trials.
Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the…
Press Release: Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results
3 April 2024 Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may slow the progression of motor symptoms in Parkinson’s disease. The study is published on 4 April in The New England Journal of…
Upcoming GBA1 conference in Montreal
Cure Parkinson’s is co-sponsoring a large three-day international conference on June 27th – 29th that will be focused on all aspects of GBA1 research, from basic science to clinical trials.
Time to ROCK-PD
Researchers in Germany are conducting a new phase 2 clinical trial to determine if an existing cardiovascular drug called fasudil, could help people with Parkinson’s.